







THE TRICVALVE SOLUTION



Pre-procedure and post-procedure volumes in the right heart chambers⁽⁵⁾ after **TricValve** implantation in SVC and IVC. **Heart remodeling** is due to the reduction of liquid congestion by abolishing the blood backflow at the superior and inferior vena cava.



TTE showing the tricuspid valve **leaflet gap** before the TricValve procedure vs a **competent leaflet coaptation** after the TricValve procedure due to tissue approximation.



Doppler echo showing previous **reversal flow in the hepatic veins** vs **abolition of backflow** after TricValve procedure.



www.productsandfeatures.com




AUSTRIA
P+F Products + Features GmbH
Wigandgasse 5
1190 Vienna | Austria

GERMANY
P+F Products + Features GmbH
Argelsrieder Feld 1a
82234 Wessling | Germany
phone: +49 8153 99 70 930
info@productsandfeatures.com

BRAZIL
PRODUCTS AND FEATURES BRASIL
PESQUISA E DESENVOLVIMENTO LTDA
R. Joaquim Rodrigues, 1085, Box 23,
Parque Tecnológico
15092-676 São Jose do Rio Preto/SP, Brazil

TRICVALVE® TRANSCATHETER BICAVAL VALVES

CE 1434



THE ONLY COMPLETE SOLUTION TO TREAT
TRICUSPID REGURGITATION AND RIGHT HEART FAILURE

 **P&F PRODUCTS & FEATURES**
GmbH

 **P&F PRODUCTS & FEATURES**
GmbH

P.F.HV01.BR.001.VER 02

TRICUSPID REGURGITATION AND CAVAL REFLUX

The **Right Heart disease** due to Tricuspid Regurgitation (TR) is a prevalent and undertreated condition. TR has a low survival rate independently of baseline clinical characteristics and optimal medical management with diuretics⁽¹⁾.

Due to comorbidities, these patients are often considered to be of **high risk for surgery**^(2,3).

Transcatheter therapies such as TricValve can be considered as a **safe and less invasive** option for these patients⁽²⁾.


34-45%

Survival at 5 years for moderate to severe TR

8-13%

Surgery mortality risk

CONDITION OF PATIENTS WITH CLINICALLY RELEVANT TR



PARAMETERS TO BE CONSIDERED FOR TRICVALVE THERAPY

Tricuspid regurgitation and caval reflux must be present, ventricular function must be preserved.

✓ V-Wave in SVC & IVC $\geq 15\text{mmHg}$

✓ TAPSE $\geq 12\text{mm}$

✓ sPAP $\leq 65\text{mmHg}$

✓ LVEF $\geq 30\%$

THE TRICVALVE SYSTEM

TricValve is a minimally invasive transcatheter bicaval system for patients with TR and significant symptoms of **Right Heart Failure**


The implantation of self-expanding valves into the superior (SVC) and inferior (IVC) vena cava effectively **abolishes Caval Reflux** and increases cardiac output by reducing backward regurgitant flow in patients with clinically relevant TR.

This will help **eliminate peripheral venous congestion** reducing right heart failure symptoms and improving the overall clinical condition of the patients⁽⁴⁾:


➤ **Improvement of NYHA functional class**

➤ **Improvement in the 6 Minute Walk Test Distance**

➤ **Improvement in quality of life (KCCQ)**



POST-PROCEDURE CLINICAL IMPROVEMENT⁽⁴⁾



1. Benfari G, Antoine C, Miller WL, et al. Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction. *Circulation*. July 16, 2019;140(3):196-206. doi:10.1161/CIRCULATIONAHA.118.038946.

2. Goliash G, Mascherbauer J. Interventional treatment of tricuspid regurgitation: an important innovation in cardiology. *Wien Klin Wochenschr*. February 2020;132(3-4):57-60. doi:10.1007/s00508-020-01621-0

3. Enriquez-Sarano M, Messika-Zeitoun D, Topilsky Y, et al. Tricuspid regurgitation is a public health crisis November 9, 2019. *Prog Cardiovasc Dis*. November-December 2019;62(6):447-451. doi:10.1016/j.pcad.2019.10.009

4. Preliminary findings in TRICUS/TRICUS EURO Study: Safety and Efficacy of the TricValve® Transcatheter Bicaval Valves System in the Superior and Inferior Vena Cava in Patients With Severe Tricuspid Regurgitation

5. As observed by a CT scan follow-up carried out in Hospital Clinico de Valladolid. Dr. Ignacio Amat-Santos and Dr. Alfredo Redondo Diéguez

TricValve is a CE marked device commercially available in EU / Non-EU territories. These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use provided inside the product package. For more information please visit our website:

<https://productsandfeatures.com/2022> © P+F Products + Features GmbH